Regulation of skeletal muscle mitochondrial fatty acid metabolism in lean and obese individuals\textsuperscript{1–4}

Graham P Holloway, Arend Bonen, and Lawrence L Spriet

ABSTRACT

A reduction in fatty acid (FA) oxidation has been associated with lipid accumulation and insulin resistance in skeletal muscle of obese individuals. Numerous reports suggest that the reduction in FA oxidation may result from intrinsic mitochondrial defects, although little direct evidence has been offered to support this conclusion. This brief review summarizes recent work from our laboratory that reexamined whether this decrease in skeletal muscle FA oxidation with obesity was attributable to a dysfunction in FA oxidation within mitochondria or simply to a reduction in muscle mitochondrial content. Whole-muscle mitochondrial content and FA oxidation was reduced in the obese, but there was no decrease in the ability of isolated mitochondria to oxidize FA. The mitochondrial content of the transport protein, FA translocase (FAT/CD36), did not differ between lean and obese women but was correlated with mitochondrial FA oxidation. It was concluded that the reduced FA oxidation in obesity is attributable to decreased muscle mitochondrial content and not intrinsic defects in mitochondrial FA oxidation, and that mitochondrial FAT/CD36 is involved in regulating FA oxidation in human skeletal muscle. The reduced skeletal muscle mitochondrial content with obesity may result from impaired mitochondrial biogenesis. However, this did not result from decreased protein contents of various transcription factors, because peroxisome proliferator-activated receptor \(\gamma\) coactivator \(1\alpha\) (PGC1\(\alpha\xspace\)), PGC1\(\beta\xspace\), peroxisome proliferator-activated receptor \(\alpha\) (PPAR\(\alpha\xspace\)), and mitochondrial transcription factor A (TFAM) were not reduced with obesity. In contrast, it appears that obesity is associated with altered regulation of cofactors (PGC1\(\alpha\xspace\) and PGC1\(\beta\xspace\)) and their downstream transcription factors (PPAR\(\alpha\xspace\), PPAR\(\beta\xspace\), and TFAM), because relations among these variables were present in muscle from lean individuals but not from obese individuals. These findings imply that obese individuals would benefit from interventions that increase the mitochondrial content and the potential for oxidizing FAs.

FA TRANSPORT ACROSS THE MUSCLE AND MITOCHONDRIAL MEMBRANES

For many years, it was believed that the transport of FA across the plasma membrane in skeletal muscle occurred only via passive diffusion. However, in recent years, a substantial body of literature has emerged indicating that FA uptake into skeletal muscle cells also occurs via a protein-mediated process [for review see Bonen et al (3)]. A number of proteins have been shown to facilitate the uptake of FA into cells, including FA translocase, the homolog of human CD36 (FAT/CD36) (4); a family of FA transport proteins (FATP1-6) (5); and plasma membrane–associated FA binding protein (FABPpm) (6). Considerable evidence has accumulated to indicate that FAT/CD36 and FABPpm are present on the muscle membrane and are important in regulating the uptake of FA into skeletal muscle. Little is currently known about the importance of FATP1-6.

In skeletal muscle, the long-chain FA transport proteins are located in several subcellular domains (7), and recently FAT
OBESITY AND MITOCHONDRIAL FUNCTION

Obese individuals have increases in IMTG storage, and this has been associated with insulin resistance (14–16). However, it appears likely that increases in IMTG levels simply represent a dysfunction in lipid metabolism (17) and that the more reactive lipid species, diacylglycerol (DAG), and ceramides may be important for the development of insulin resistance (18, 19). It has been shown in skeletal muscle from nondiabetic lean and obese women that the transport of FA into giant sarcolemmal vesicles was increased 4-fold with obesity and coincided with an increase in the plasma membrane content of FAT/CD36 (20). There were no increases in the total muscle expression of FAT/CD36 or FABPpm with obesity, suggesting that a permanent redistribution of FAT/CD36 to the plasma membrane occurred (20). This also provided evidence for a potential mechanism for elevating intramuscular lipid species and inducing insulin resistance.

It has also been suggested that reductions in FA oxidation in obese individuals contribute to IMTG accumulation (21–24). On the basis of reductions in whole-muscle CPTI activity in skeletal muscle from obese individuals, it has been proposed that FA transport into the mitochondria is diminished. This may account for the observed reduction in whole-muscle FA oxidation (22). It is possible that this reflects a decrease in mitochondrial content, although other proteins may also be involved.

Are mitochondria from skeletal muscle from obese individuals dysfunctional?

The net accumulation of lipids in obese skeletal muscle may result from a combination of increased whole-muscle FA uptake and/or decreased whole-muscle oxidation. Although the concept of impaired FA oxidation as a mechanism to increase intramuscular lipid species has gained attention in recent years, the exact mechanisms remain unknown. However, 3 plausible explanations exist: 1) mitochondrial content is decreased, 2) there is a dysfunction in FA oxidation within mitochondria, or 3) both of these conditions occur. Previous work in skeletal muscle indicated a reduction in mitochondrial content with obesity along with a concomitant decrease in FA oxidation (21), suggesting that mitochondria from obese individuals contain an inherent dysfunction to oxidize FA. In some studies the ratios of electron transport chain capacity to mitochondrial DNA (mtDNA) and size have been used to infer mitochondrial dysfunction for FA oxidation (21, 23). It has also been suggested that the relative proportion of FAs that are completely oxidized is decreased with obesity (25). Because β oxidation is regulated by substrate and product concentrations, an imbalance among β oxidation, the tricarboxylic acid cycle, and electron transport chain activities would increase the amount of acyl-CoAs located within the cell. This may have deleterious effects and could induce oxidative damage in mitochondria and induce apoptosis, although this remains speculative. In addition, more FAT/CD36 is located on the plasma membrane without total expression being altered in the obese state. It is therefore possible that less would be available for mitochondria, potentially compromising oxidation and explaining the previously observed “mitochondrial dysfunction” in the obese state.

It should be mentioned that not all studies have reported decreased mitochondrial function with obesity. A recent study that measured the ability of mitochondria to oxidize FA directly in skeletal muscle from obese patients with type 2 diabetes reported the controversial finding of increased FA oxidation (26). However, this finding may not be directly applicable to the obese nondiabetic population and the underlying mechanism remains unknown.

Skeletal muscle mitochondria are not dysfunctional in obesity

Recent work in our laboratory focused on examination of whether obesity-related decreases in skeletal muscle lipid oxidation were attributable to a reduction in mitochondrial content or an intrinsic defect in mitochondria, and whether there were reductions in the content of mitochondrial FA transport proteins. We hypothesized that nondiabetic obesity would be associated with decreases in skeletal muscle mitochondrial content, as well as decreases in the ability of mitochondria to oxidize FA. In addition, we speculated that impairments in mitochondrial oxidation would be associated with reductions in the content of mitochondrial FAT/CD36 and FABPpm.

In age-matched lean [body mass index (BMI; in kg/m²): 23.3 ± 0.7] and obese (BMI: 37.6 ± 2.2) individuals, citrate synthase (CS) and β-hydroxyacyl-CoA dehydrogenase (β-HAD) activities, common markers of total muscle mitochondrial volume and the capacity for FA oxidation, were decreased in muscle from obese individuals (27). This suggested that a decrease in mitochondrial volume was present and appeared to account for the observed reductions in FA oxidation, because isolated mitochondrial palmitate oxidation was not altered in muscle from obese subjects (Figure 1). In addition, mitochondrial FAT/CD36 and FABPpm content did not differ between...
lean and obese individuals when normalized to mitochondrial protein content (Figure 2). In summary, the mitochondria isolated from obese individuals were not dysfunctional. There simply was less mitochondrial volume and lower rates of whole-muscle FA oxidation.

An interesting finding was that, although mitochondrial palmitate oxidation rates in lean and obese individuals did not correlate with BMI, the rates strongly correlated with mitochondrial FAT/CD36 content (Figure 3). On the other hand, FABPpm did not correlate with mitochondrial oxidation, suggesting that it is not rate limiting for FA mitochondrial transport. Although this requires additional investigation, the main function of FABPpm appears to be related to transporting reducing equivalents into the mitochondria (12, 13).

Data from a previous study suggested that mitochondrial FA oxidation impairment may only be manifested above a certain threshold (ie, BMI of 40–50), although mitochondrial function was not directly measured in that study (24). In our study, the BMI in the obese group was relatively high (x: 37.6) but there was no mitochondrial dysfunction, so it is possible that the subjects were below this threshold. The obese group displayed reductions in whole-muscle CS and β-HAD activities and reduced whole-muscle FA oxidation rates, indicating that lipid oxidation was compromised. Thus, the current data again suggest that the reductions in FA oxidation that have been associated with obesity result from reductions in mitochondrial content, and not from intrinsic mitochondrial alterations. This is an important distinction because it suggests that interventions are required to increase overall mitochondrial biogenesis, without any “remodeling” of existing mitochondria. Indeed, previous work showed that regular exercise increased CS, β-HAD, and CPTI activities and therefore mitochondria volume in an obese population (28). Associated with these changes were increases in FA oxidation, reductions in total DAG and total ceramide contents, and improved insulin sensitivity (28).

We originally hypothesized that mitochondria from obese individuals would display an impaired ability to oxidize FA. It has been suggested that subsarcolemmal (SS) mitochondria from obese individuals may display a disproportionate impairment in FA oxidation, because a greater reduction in the ratio of electron transport chain activity to mtDNA was observed in this mitochondrial fraction (23). The SS fraction represents only ≈25% of the total mitochondria in skeletal muscle (29). In our study we pooled the SS mitochondria with the intermyofibrillar (IMF) mitochondria to ensure that adequate protein was recovered for our functional assays (27). Although this approach limited our

FIGURE 1. Effects of obesity on the ability of skeletal muscle to oxidize palmitate. Values are means ± SEs (n = 9). A: Isolated mitochondrial palmitate oxidation (expressed in nmol·mg protein⁻¹·h⁻¹). B: Calculated whole-muscle palmitate oxidation (expressed in nmol·g wet weight (ww)⁻¹·h⁻¹). *Significantly different from lean, P < 0.05.

FIGURE 2. Representative Western blots displaying the effects of obesity on the expression of mitochondrial proteins. Values are means ± SEs, expressed in arbitrary units (n = 9). Data are normalized to mitochondrial protein content. A: Mitochondrial FA translocase (FAT/CD36) content. B: Mitochondrial plasma membrane–associated FA binding protein (FABPpm) content. C: Mitochondrial Cox-IV content.
creasing BMI as a result of reductions in mitochondrial content, is, whereas whole-muscle FA oxidation may decrease with in-

tainum’’ may exist in mitochondrial oxidation with obesity. That increased. Together, these studies suggest that a ‘‘reverse con-

In the study by our laboratory, obese participants actually displayed a trend (P = 0.12) toward an increase in the capacity of mitochondria to oxidize FA (27). Previously, Bandyopadhyay et al (26) reported that the mitochondrial capacity to oxidize FA in obese patients with type 2 diabetes (BMI: 36.9) was actually increased. Together, these studies suggest that a ‘‘reverse continuum’’ may exist in mitochondrial oxidation with obesity. That is, whereas whole-muscle FA oxidation may decrease with increasing BMI as a result of reductions in mitochondrial content, the capacity of the remaining mitochondria to oxidize FA may actually compensate by increasing oxidation in an undetermined manner to counteract this effect. Although a clear increase in mitochondrial FA oxidation in muscle from obese and diabetic populations has not been clearly established, there is no suggestion of a decrease.

Other evidence that mitochondrial function is normal in obesity

Two additional recent studies that directly measured the oxygen consumption of mitochondria isolated from lean and obese diabetic individuals concluded that there was no mitochondrial dysfunction in skeletal muscle from obese individuals. Boushel et al (30) demonstrated that whole-muscle FA oxidation was impaired with obesity. However, when the data were normalized to CS activity or mtDNA, this finding was lost, again indicating that obese diabetic individuals simply have less mitochondria in their skeletal muscle. Of importance, Boushel et al (30) measured oxygen consumption instead of radioactively labeled substrate consumption, which enables mitochondrial respiration to be measured in state 4 (quiescent) and state 3 (ADP-stimulated) conditions. This provided an indication of the metabolic responsiveness of the mitochondria. These measures provided additional evidence that mitochondria do not have an intrinsic dysfunction, because the respiratory control ratio (RCR, state 3/state 4) was similar between patients with diabetes and lean controls (30). Of interest, in another laboratory, Mogensen et al (31) reported a reduction in oxygen consumption in mitochondria isolated from individuals with type 2 diabetes compared with obese individuals, and associated with this was a reduction in the RCR value. However, these results were only observed when pyruvate and malate were used as substrates. When palmitoylcarnitine was used (the product of CPTI, thereby removing any differences in this enzyme from compromising the interpretation), no dysfunction was observed in oxygen consumption or in the RCR values, again implying normal functioning mitochondria (31).

It appears that at least 4 publications have now demonstrated that mitochondria isolated from obese (nondiabetic and diabetic) individuals do not contain an inherent dysfunction (26, 27, 30, 31). However, we must remember that the mitochondrial isolation techniques used in 3 of these studies may alter the morphology of mitochondria and that only ∼20% of the total mitochondria are recovered (26, 27, 31). Therefore, it is possible that a mitochondrial dysfunction affecting FA oxidation may be present in vivo, and newer methodologies will be needed to fully confirm the data supporting the findings that mitochondrial function in the skeletal muscle of obese individuals is normal. However, Boushel et al (30) used a permeabilized-muscle technique that avoids some of these problems and reported similar findings.

WHY IS MITOCHONDRIAL CONTENT REDUCED IN OBESITY?

The reduced ability of skeletal muscle to oxidize FA with obesity appears to be a function of reduced mitochondrial content. This may result from lower physical activity levels in obese individuals and ultimately from reduced or impaired mitochondrial biogenesis. It is possible that decreases in the general transcription factors that regulate mitochondrial biogenesis are
responsible for the obesity phenotype as a result of a genetic predisposition and/or a sedentary lifestyle.

The coordination between mtDNA and nuclear DNA transcription is a key component of mitochondrial biogenesis. Peroxisome proliferator activated receptor \( \gamma \) coactivator 1 \( \alpha \) (PGC1\( \alpha \)) has been considered the “master regulator” coordinating these events (32), because overexpression of PGC1\( \alpha \) results in increases in both nuclear and mitochondrial proteins (33). It has also become apparent that PGC1\( \alpha \) coordinates these events by activating downstream transcription factors, including nuclear respiratory factor 1 (NRF-1) (34) and NRF-2 (35). Peroxisome proliferator activated receptor \( \gamma \) coactivator 1 \( \beta \) (PGC1\( \beta \)) has not been studied to the
same extent as PGC1α. However, it has also been implicated in the proliferation of mitochondria in skeletal muscle (36) and its overexpression prevented diet-induced insulin resistance (37).

Reductions in PGC1α and PGC1β have been linked to the presence of skeletal muscle insulin resistance because the mRNAs of these proteins were decreased with diabetes (38, 39), and single nucleotide polymorphisms in PGC1α and PGC1β (40, 41) have been reported in obesity and diabetes. However, the picture is not totally clear because reductions in PGC1α and PGC1β expression are not always present with insulin resistance (42), and research in humans has been limited mainly to mRNA data and not protein measurements. The role of PGC1α protein in obesity-related insulin resistance in rodent muscle is also unclear, because ablating PGC1α unexpectedly improved glucose tolerance and insulin sensitivity in mice consuming a high-fat diet (43), and overexpressing PGC1α in mice unexpectedly induced insulin resistance (44). This may be attributable to a massive PGC1α up-regulation that increases the accumulation of intramuscular lipids to a greater extent than the increased capacity for their oxidation (45).

Given the prominent roles of PGC1α and PGC1β and their downstream targets (eg, peroxisome proliferator-activated receptors (PPARs) and mitochondrial transcription factor A (TFAM)) in regulating mitochondrial biogenesis and the capacity to oxidize FA in muscle, we sought to determine 1) whether PGC1α and PGC1β protein contents are reduced in the skeletal muscle of obese individuals, and 2) whether the protein content of other transcription factors located downstream of PGC1α and β (PPARγ, PPARδ/β, PPARα, and TFAM) are also reduced in the skeletal muscle of obese individuals.

Of interest, obesity did not alter the skeletal muscle protein content of PGC1α and PGC1β (Figure 4), PPARα, or TFAM (46). In contrast, there was a significant 22% increase in PPARγ and a nonsignificant 31% increase (P = 0.13) in PPARδ/β.

**FIGURE 6.** Relations between peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) and peroxisome proliferator activated receptors (PPARs) in lean and obese individuals. Values are expressed in arbitrary units, normalized to Ponceau staining (n = 9 for lean and obese).
PGC1α was significantly correlated with palmitate oxidation in lean participants, but this relation was lost in obese individuals (Figure 5). In contrast, PGC1β protein content did not correlate with palmitate oxidation in lean and obese individuals. PGC1α protein expression did not correlate with PPARγ, PPARα, or PPARδ/β in lean participants, but did significantly correlate with both PPARα and PPARδ/β in obese individuals (Figure 6).

The novel findings of this study were that obesity did not decrease the protein content of PGC1α, PGC1β, PPARα, PPARδ/β, or TFAM, and that compensatory increases in PPARγ occurred with obesity. In addition, PGC1α correlated with palmitate oxidation in the lean individuals only, and PGC1β correlated with PPARγ and PPARδ/β in lean individuals only. The latter 2 findings suggest that the coordinated regulation of selected transcription factors involved in mitochondrial biogenesis was lost with obesity. The concept that reduced PGC1α expression is the explanation for the observed reduction in FA oxidation with insulin resistance associated with obesity is not supported by these recent data. The PGC1α protein was not reduced in the skeletal muscle of obese individuals, whereas the muscle mitochondrial content was markedly reduced (27). Although these findings contradict much of the literature regarding PGC1α mRNA data, mRNA changes are only weakly associated with changes in PGC1α protein (47) and there is only a modest relation between skeletal muscle insulin sensitivity and PGC1α mRNA (48). In support of our findings, a recent publication reported no change in either PGC1α mRNA or total protein with obesity (49). These observations underscore the complexity of mechanisms that regulate protein expression, including the influence of phosphorylation on increasing PGC1α mRNA stability (50) or activation (51), the ability of other proteins to suppress PGC1α activity (52), and the importance of nuclear import (53). Puigserver and colleagues (54) have proposed a 3-step model of activation that includes PGC1α interacting and docking with transcription factors, undergoing a conformational change that enables binding of additional cofactors, and subsequent induction of transcription. Clearly this is a complex process, and one should use caution when interpreting data that provide insight into only one of these 3 steps. However, the current data suggest that the reduction in mitochondrial content associated with obesity does not involve diminished PGC1α protein, and may be located downstream of PGC1α and involve activation or repression.

CONCLUSIONS

In conclusion, recent literature demonstrates that obesity does not alter the ability of skeletal muscle mitochondria to oxidize FA. In our laboratory, we observed that obesity-related reductions in skeletal muscle FA oxidation are attributable to reductions in mitochondrial content and not to intrinsic alterations, or dysfunction, within the mitochondria. We further demonstrated that the content of FAT/CD36 on mitochondria is not different in obese muscle. However, FAT/CD36 significantly predicted the ability of mitochondria to oxidize FA, independently of BMI status. We also revealed that obesity is not associated with reductions in the protein contents of PGC1α or PGC1β in skeletal muscle, and that the PPARs (γ and potentially δ/β) may be up-regulated in response to the decreases in lipid oxidation associated with obesity. The relation between PGC1α and palmitate oxidation was also lost with obesity, as were the relations among PGC1β, PPARγ, and PPARδ/β. These data suggest that the regulation of PGC1α and PGC1β, and not total protein, is altered with obesity. These findings imply that obese individuals would benefit from interventions that increase the skeletal muscle mitochondrial content and the potential for oxidizing FAs. (Other articles in this supplement to the Journal include references 55 and 56.)

All authors contributed equally to this work and the writing of the paper. The authors stated that they have no conflicts of interest with respect to the published work contained in this paper.

REFERENCES

26. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006;55:2277–85.
56. Lanza IR, Nair KS. Muscle mitochondrial changes with aging and exercise. Am J Clin Nutr 2009;89(suppl):71S–71S.